On April 19th, the "Forum on the Internationalization of TCM Regulation and Achievement Transformation", hosted by the University of Macau and undertaken by Ai She Kang (Shanghai) Health Consulting Co., Ltd., successfully concluded. As a professional force deeply involved in the commercialization and industrialization of biopharmaceuticals, Xinghan Biotechnology was honored to be invited to participate. Mr. Liu Weimin, Vice President of the company, was invited to attend and serve as a guest speaker for the roundtable dialogue, and attended with many entrepreneur partners to jointly explore effective paths for going global.

This forum focused on the two core directions of "Internationalization of TCM Regulation" and "University Achievement Transformation", bringing together regulatory government representatives, top universities, research institutes, and industry representatives from mainland China, Hong Kong, Macao, as well as Singapore, Indonesia, and other places. The event aims to explore feasible paths for Macao as a gateway for international cooperation in Traditional Chinese Medicine, promote the deep integration of industry, academia, and research in TCM, and facilitate the landing of innovative achievements, thereby helping the TCM industry to go global with high quality.

During the forum, several roundtable dialogues were held around topics such as international cooperation, capital matchmaking, and cultural reshaping. The specially set up "Industry-Academia-Research Implementation" session witnessed the signing ceremony of the University of Macau Innovation and Entrepreneurship Center and the roadshows of four excellent startup projects, providing a practical matchmaking platform for scientific research achievements to move from the laboratory to industrialization.

In the second roundtable discussion, "Unblocking the Innovation Chain: Capital Dialogue and Transformation Breakthroughs in TCM Industry-Academia-Research", Mr. Liu Weimin, Vice President of Xinghan Biotechnology, as an industry representative, engaged in dialogue with academic, investment, and research experts from the University of Macau, Hengqin Research Institute, Ransheng Industrial, Fujian Capital, and Reheart Institute.

Bwana Liu Weimin alishiriki mazoea na mawazo ya Xinghan kuhusu masuala muhimu kama vile "Jinsi mitaji ya bioteknolojia inavyoweza kusaidia utafiti wa awali na utekelezaji wa viwanda wa dawa za jadi za Kichina" na "Tathmini ya hatari na fursa katika ushirikiano kati ya sekta ya elimu, utafiti na viwanda". Alibainisha kuwa katika wimbi la kisasa na kimataifa la dawa za jadi za Kichina, makampuni maalumu ya bioteknolojia hucheza jukumu la "daraja muhimu" linalounganisha mafanikio ya juu ya utafiti na matumizi ya soko kwa kiwango kikubwa. Uingiliaji mzuri wa mtaji haupaswi tu kuwa mdogo kwa msaada wa kifedha, lakini pia unahitaji kuelewa kwa kina sheria za utafiti wa kisayansi, kushiriki katika kubuni njia za ubadilishaji, na kuunganisha rasilimali za mnyororo wa viwanda, ili kufikia mzunguko wa thamani kutoka kwa maabara hadi kitandani.

Jukwaa hili la kimataifa la kiwango cha juu limetoa fursa muhimu kwa Xinghan Biotechnology kubadilishana kwa kina na mashirika ya udhibiti duniani, viongozi wa kitaaluma na washirika wa uwekezaji. Tunatoa shukrani za dhati kwa waandaaji kwa upangaji wao wa uangalifu na mwaliko, kuruhusu sauti za tasnia kueleza kikamilifu kwenye jukwaa ambapo sera na taaluma hukutana.

Through this event, Xinghan not only showcased its professional insights in biopharmaceutical investment and industrialization to the industry, but also established extensive connections with potential partners from multiple countries and regions. In the future, Xinghan will continue to uphold the concept of "Connecting Science, Empowering Health", deeply participate in the modernization and internationalization of Traditional Chinese Medicine, actively empower the transformation of cutting-edge scientific research achievements, and work hand in hand with partners from all walks of life to jointly promote the innovative development of the big health industry.